Sacituzumab tirumotecan plus pembrolizumab versus pembrolizumab in PD-L1-positive advanced non-small-cell lung cancer (OptiTROP-Lung05): interim analysis of a randomised, open-label, phase 3 trial

The Lancet 2026

View at publisher
Authors: Anwen Xiong, Wenxiu Yao, Wei Zheng, Yu Yan, Peng Chen, Hua Zhong, Junyou Ge, Hui Wang, Bolin Chen, Haiyong Wang, Yun Fan, Yunpeng YANG
+24 more Xingxiang Pu, Xia Song, Qiming Wang, Xiaobo Du, Zhangzhou Huang, Xingya Li, Hui Luo, Yu Yao, Qitao Yu, Cuiyun Su, Lang He, Guanming Jiang, Jiuwei Cui, Chunling Liu, Tienan Yi, Guowei Che, Zhentian Liu, Lemeng Zhang, Ming Zhou, Yong Fang, Youneng Wei, Yan Qing, Xiaoping Jin, Caicun Zhou
DOI: 10.1016/s0140-6736(26)00968-2
Cited by: 8
References: 33

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Lung Cancer Treatments and Mutations Lung Cancer Diagnosis and Treatment

Publication details

Journal / source
The Lancet
Publisher
Elsevier BV
Volume
407
Issue
10548
Pages
2607–2619
Publication date
29 May 2026
Language
EN